Family Intervention in Recent Onset Schizophrenia Treatment (FIRST)

CompletedOBSERVATIONAL
Enrollment

296

Participants

Timeline

Start Date

July 24, 2015

Primary Completion Date

July 5, 2018

Study Completion Date

July 5, 2018

Conditions
Schizophrenia
Interventions
OTHER

Caregiver psycho-education and skills training

Caregivers will receive up to 16 sessions of study-provided caregiver psycho-education and skills training sessions they are able to attend within a 6-month period.

OTHER

Caregiver support available at the study site

Caregivers will receive whatever caregiver support that is customarily available at the study site, if any.

DRUG

Paliperidone palmitate

Patients enrolled in this study will continue to receive routine treatment of paliperidone palmitate, as directed by their treating physician.

DRUG

Chlorpromazine

Patients enrolled in this study will continue to receive routine treatment of oral antipsychotics, as directed by their treating physician.

DRUG

Droperidol

Patients enrolled in this study will continue to receive routine treatment of oral antipsychotics, as directed by their treating physician.

DRUG

Fluphenazine

Patients enrolled in this study will continue to receive routine treatment of oral antipsychotics, as directed by their treating physician.

DRUG

Haloperidol

Patients enrolled in this study will continue to receive routine treatment of oral antipsychotics, as directed by their treating physician.

DRUG

Loxapine

Patients enrolled in this study will continue to receive routine treatment of oral antipsychotics, as directed by their treating physician.

DRUG

Perphenazine

Patients enrolled in this study will continue to receive routine treatment of oral antipsychotics, as directed by their treating physician.

DRUG

Pimozide

Patients enrolled in this study will continue to receive routine treatment of oral antipsychotics, as directed by their treating physician.

DRUG

Prochlorperazine

Patients enrolled in this study will continue to receive routine treatment of oral antipsychotics, as directed by their treating physician.

DRUG

Thiothixene

Patients enrolled in this study will continue to receive routine treatment of oral antipsychotics, as directed by their treating physician.

DRUG

Thioridazine

Patients enrolled in this study will continue to receive routine treatment of oral antipsychotics, as directed by their treating physician.

DRUG

Trifluoperazine

Patients enrolled in this study will continue to receive routine treatment of oral antipsychotics, as directed by their treating physician.

DRUG

Aripiprazole

Patients enrolled in this study will continue to receive routine treatment of oral antipsychotics, as directed by their treating physician.

DRUG

Asenapine

Patients enrolled in this study will continue to receive routine treatment of oral antipsychotics, as directed by their treating physician.

DRUG

Clozapine

Patients enrolled in this study will continue to receive routine treatment of oral antipsychotics, as directed by their treating physician.

DRUG

Iloperidone

Patients enrolled in this study will continue to receive routine treatment of oral antipsychotics, as directed by their treating physician.

DRUG

Olanzapine

Patients enrolled in this study will continue to receive routine treatment of oral antipsychotics, as directed by their treating physician.

DRUG

Paliperidone

Patients enrolled in this study will continue to receive routine treatment of oral antipsychotics, as directed by their treating physician.

DRUG

Quetiapine

Patients enrolled in this study will continue to receive routine treatment of oral antipsychotics, as directed by their treating physician.

DRUG

Risperidone

Patients enrolled in this study will continue to receive routine treatment of oral antipsychotics, as directed by their treating physician.

DRUG

Ziprasidone

Patients enrolled in this study will continue to receive routine treatment of oral antipsychotics, as directed by their treating physician.

Trial Locations (34)

Unknown

Bullhead City

Oceanside

Denver

Farmington

Lauderdale Lakes

Leesburg

Miami

Orange City

Tallahassee

West Palm Beach

Atlanta

Granite City

Lombard

Springfield

Bloomington

Lawrenceburg

Ann Arbor

Grand Rapids

Mount Pleasant

Kansas City

St Louis

New York

Staten Island

Toledo

Oklahoma City

Eugene

Lincoln

Nashville

Austin

Fort Worth

San Antonio

Salt Lake City

Richland

Spokane

All Listed Sponsors
lead

Janssen Scientific Affairs, LLC

INDUSTRY

NCT02600741 - Family Intervention in Recent Onset Schizophrenia Treatment (FIRST) | Biotech Hunter | Biotech Hunter